<DOC>
	<DOCNO>NCT01827605</DOCNO>
	<brief_summary>This Phase III , multicenter , open-label , randomize control study compare efficacy consolidation therapy RIT versus ASCT patient FL CR PR second third line chemotherapy supplement rituximab .</brief_summary>
	<brief_title>A Phase III Multicenter , Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan ( Zevalin® ) Radioimmunotherapy Versus Autologous Stem Cell Transplantation ( ASCT ) Patients With Relapsed/Refractory Follicular Lymphoma ( FL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age 1865 Histologically document diagnosis grade IIIIa FL define accord WHO guideline 2008 ( Rebiopsy require ) Availability BM PB Minimal Residual Disease ( MRD ) analysis ( see Appendix I ) Relapsed refractory disease ≤ two chemotherapy line least one contain Rituximab ( Rituximab maintenance UNOTU consider therapeutic line ) Clinical indication treatment i.e . Stage IIIV require therapy accord SIE GELF criterion ( see Appendix II ) ECOG performance status 02 ( unless diseaserelated ) ( see Appendix III ) Availability histological material centralize revision Laboratory value : ANC ≥ 1500/mmc unless due marrow involvement lymphoma and/or platelet ≥ 100000/mmc unless due marrow involvement lymphoma Serum creatinine ≤ 1.5 x ULN , unless disease relate Bilirubin ≤ 1.5 x ULN ( ≤ 3.0 x ULN , patient Gilbert syndrome ) AST/SGOT and/or ALT/SGPT ≤ 2.5 x ULN lymphoma relate ≤ 5.0 x ULN case lymphoma liver involvement Adequate cardiac function : LVEF &gt; 50 % echocardiography MUGA scan Not pregnant breastfeed Willingness use effective contraception study 3 month end treatment No prior malignancy except adequately treat nonmelanoma skin cancer , carcinoma situ cervix , cancer patient diseasefree ≥ 5 year ( see Exclusion criterion 14 ) Signed inform write consent Grade IIIb FL , transform FL histology different FL Previous treatment &gt; two line chemotherapy ± rituximab Maintenance UNOTU consider therapeutic line ) Previous ASCT RIT treatment CNS involvement lymphoma HBV positivity exception patient seropositive hepatitis B virus vaccination patient HbcAb positive HbsAg negative undetectable serum HBVDNA . Occult carrier : must receive treatment Lamivudine 100 mg duration treatment program least 12 month treatment cessation ; HBVDNA level HBsAg monitor every month HCV positivity elevate transaminase INR APTT active virus replication HIV positivity Any concurrent medical condition require long term use ( &gt; one month ) systemic corticosteroid Active bacterial , viral , fungal infection require systemic therapy Any concurrent medical psychiatric condition might impair administration therapy preclude ability give inform consent Treatment experimental agent within 30 day prior study entry Myelosuppressive chemo biological therapy within three week study entry ( use rituximab course deliver maintenance exclusion therapy ) Major surgery diagnosis within 4 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Relapsed follicular Lymphoma</keyword>
	<keyword>RIT</keyword>
	<keyword>Zevalin</keyword>
</DOC>